世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

組換えタンパク質市場：製品（成長因子、ケモカイン、構造タンパク質、膜タンパク質）、用途（創薬・開発、バイオ医薬品生産、研究、診断）、エンドユーザー（バイオテクノロジー、CRO）別 - 2027年までの世界予測


Recombinant Proteins Market by Product (Growth Factors, Chemokines, Structural Proteins, Membrane Proteins), Application (Drug Discovery & Development, Biopharma Production, Research, Diagnostics), End User (Biotech, CROs) - Global Forecast to 2027

組み換えタンパク質の世界市場は、2022年の14億米ドルから2027年には24億米ドルに達すると予測され、予測期間中のCAGRは11.4%となります。市場成長の主な要因は、製薬・バイオテクノロジー企業や学術研究機関への... もっと見る

　

　

出版社 出版年月 電子版価格 ページ数 図表数 言語
MarketsandMarkets
マーケッツアンドマーケッツ 		2022年11月4日 US$4,950
シングルユーザーライセンス
ライセンス・価格情報・注文方法はこちら 		237 234 英語

日本語のページは自動翻訳を利用し作成しています。


　

サマリー

組み換えタンパク質の世界市場は、2022年の14億米ドルから2027年には24億米ドルに達すると予測され、予測期間中のCAGRは11.4%となります。市場成長の主な要因は、製薬・バイオテクノロジー企業や学術研究機関への政府投資や研究開発費の増加、慢性疾患や感染症の高い流行に伴う重要な診断用遺伝子組換えタンパク質の必要性などによるものです。しかし、価格競争力のある製品や労働集約的で収率の低い組換えタンパク質が市場に参入することで、市場の成長がある程度制限される可能性があります。


"製薬・バイオ製薬会社セグメントが予測期間中に市場を支配すると予想される。"
組換えタンパク質市場は、エンドユーザーに基づいて、製薬＆バイオ製薬会社、バイオテクノロジー企業、学術研究機関、受託研究機関、その他のエンドユーザーに区分されます。2020年のエンドユーザー市場では、製薬＆バイオ製薬会社が最大のシェアを占めています。このセグメントの大きなシェアは、ほとんどの低分子創薬プログラムの重要な構成要素として組換えタンパク質の役割があること、また、新薬アプリケーションの構造およびメカニズム研究のスクリーニングのために、創薬における組換えタンパク質の要件があることに起因しています。また、ブロックバスター薬の特許切れなども、市場の成長にプラスの影響を与えます。


"ワクチン分野は、予測期間中、組み換えタンパク質市場で2番目に高い成長を目撃するでしょう。"

タイプに基づいて、創薬＆開発市場は、生物製剤、ワクチン、細胞＆遺伝子治療に区分されます。ワクチンは、組み換えタンパク質市場の創薬＆開発アプリケーションの第2位のシェアを占め、予測期間中に2番目に高いCAGRを記録すると予想されます。ワクチン分野の大きなシェアは、インフルエンザ、ウイルス性疾患、肝炎などの疾患の発生率の増加などの要因に起因しています。このような疾患の出現は、積極的なワクチンを発見するための研究開発活動の増加につながっており、これは組換えタンパク質の市場成長を促進しています。

"予測期間中、北米が市場を支配する"
地域的には、組換えタンパク質市場は、北米、ヨーロッパ、アジア太平洋地域、ラテンアメリカ、中東・アフリカに区分されます。2021年、北米は組み換えタンパク質市場で最大のシェアを占めています。世界市場におけるこの地域の大きなシェアは、感染症や慢性疾患の有病率の上昇、政府や製薬業界による研究開発費の増加、バイオテクノロジー企業による研究活動の増加、主要な市場プレイヤーの存在に起因するものである。




本レポートのために実施した一次インタビューは、以下のように分類されます。

- 企業タイプ別 - ティア1: 36%, ティア2: 45%, ティア3: 19
- 役職別：Cレベル：33％、Dレベル：40％、その他：27
- 地域別：北米36％、欧州28％、アジア太平洋19％、中南米10％、中東・アフリカ7％。

報告書に掲載されている企業一覧
- サーモフィッシャーサイエンティフィック社（米国）
- Miltenyi Biotech（ドイツ）
- Sino Biological Inc.（中国）
- メルクKGaA（ドイツ）
- アブカム社（英国）
- バイオレジェンド（米国）
- バイオ・ラッド・ラボラトリーズ社（米国）
- GenScript Biotech Corporation（中国）
- エンゾ・ライフサイエンス社（米国）
- BPSバイオサイエンス社（米国）
- Proteintech Group, Inc.（米国）
- アブノバコーポレーション（台湾）
- R&Dシステムズ（米国）
- STEMCELL Technologies Inc (カナダ)
- RayBiotech Inc（米国）
- CellGenix GmbH（ドイツ）
- アクロバイオシステムズ社（米国）
- プロスペック・テクノジーン社（イスラエル(イスラエル)
- ニューロミクス社（米国）
- ローラウスバイオ（インド）
- Icosagen AS（米国）
- プロテオジェニックス（フランス）
- ユナイテッド・ステーツ・バイオロジカルズ（米国）
- ストレスマルク・バイオサイエンス社（カナダ）
- アビバ システムズ バイオロジー コーポレーション（アメリカ）





調査対象
本レポートは、世界の組み換えタンパク質市場の詳細図を提供します。製品、用途、エンドユーザー、地域などの異なるセグメントにおける市場規模や今後の成長性を推定することを目的としています。また、市場成長に影響を与える要因（促進要因、阻害要因、課題、機会など）を分析しています。利害関係者向けに市場の機会を評価し、市場リーダー向けに競争環境の詳細を提供しています。また、マイクロマーケットについては、その成長動向、展望、組換えタンパク質市場全体への貢献度に関して調査しています。本レポートでは、5つの主要地域に関して、市場セグメントの収益を予測しています。

レポート購入の理由
本レポートは、以下のポイントに関する洞察を提供します。
- 市場の浸透。組換えタンパク質市場の上位25社が提供する組換えタンパク質に関する包括的な情報。製品、アプリケーション、エンドユーザー、地域別に組換えタンパク質市場を分析しています。

- 市場の発展。有利な新興市場に関する包括的な情報。本レポートでは、主要な地理的地域における様々な組み換えタンパク質の市場を分析しています。

- 市場の多様化。遺伝子組み換えタンパク質市場における新製品、未開拓の地域、最近の開発、投資に関する徹底的な情報。

- 競争力の評価。組換えタンパク質市場における主要企業の市場ランキングと戦略に関する詳細な評価。

ページTOPに戻る


目次

1 INTRODUCTION 32
1.1 STUDY OBJECTIVES 32
1.2 MARKET DEFINITION 32
1.2.1 INCLUSIONS AND EXCLUSIONS 33
1.3 MARKET SCOPE 34
FIGURE 1 RECOMBINANT PROTEINS MARKET 34
1.4 YEARS CONSIDERED 35
1.5 CURRENCY CONSIDERED 35
1.6 LIMITATIONS 35
1.7 STAKEHOLDERS 35
1.8 SUMMARY OF CHANGES 36
2 RESEARCH METHODOLOGY 37
2.1 RESEARCH DATA 37
FIGURE 2 RESEARCH DESIGN 37
2.1.1 SECONDARY DATA 38
2.1.1.1 Secondary sources 38
2.1.2 PRIMARY DATA 38
2.1.2.1 Key data from primary sources 39
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 39
2.2 MARKET SIZE ESTIMATION 40
2.2.1 BOTTOM-UP APPROACH 40
FIGURE 4 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH 40
2.2.2 TOP-DOWN APPROACH 41
FIGURE 5 MARKET SIZE ESTIMATION: TOP-DOWN APPROACH 41
2.2.3 GROWTH FORECAST 41
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 42
FIGURE 6 DATA TRIANGULATION METHODOLOGY 42
2.4 ASSUMPTIONS 43
3 EXECUTIVE SUMMARY 44
FIGURE 7 RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2022 VS. 2027 (USD MILLION) 44
FIGURE 8 RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION) 45
FIGURE 9 RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 45
FIGURE 10 RECOMBINANT PROTEINS MARKET, BY END USER, 2022 VS. 2027 (USD MILLION) 46
4 PREMIUM INSIGHTS 48
4.1 RECOMBINANT PROTEINS MARKET OVERVIEW 48
FIGURE 12 INCREASING GOVERNMENT INVESTMENTS AND RISING FOCUS ON PERSONALIZED MEDICINE TO DRIVE MARKET GROWTH 48
4.2 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET, BY APPLICATION AND COUNTRY (2022) 49
FIGURE 13 DRUG DISCOVERY AND DEVELOPMENT SEGMENT TO ACCOUNT FOR LARGEST SHARE IN ASIA PACIFIC MARKET 49
4.3 RECOMBINANT PROTEINS MARKET, BY END USER, 2022–2027 50
FIGURE 14 PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES TO FORM LARGEST END-USER SEGMENT FOR RECOMBINANT PROTEINS 50
4.4 RECOMBINANT PROTEINS MARKET: GEOGRAPHIC SNAPSHOT 50
FIGURE 15 JAPAN TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 50
5 MARKET OVERVIEW 51
5.1 INTRODUCTION 51
5.2 MARKET DYNAMICS 51
FIGURE 16 RECOMBINANT PROTEINS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 51
5.2.1 DRIVERS 52
5.2.1.1 Rising government funding and increasing R&D expenditure in pharmaceutical and biotechnology companies 52
TABLE 1 GOVERNMENT FUNDING FOR LIFE SCIENCE RESEARCH (2022) 52
5.2.1.2 High prevalence of infectious and chronic diseases 53
5.2.1.3 Growing industry-academia collaborations 53
5.2.1.4 Patent expiry of biologics 54
5.2.2 RESTRAINTS 54
5.2.2.1 Declining cost of recombinant proteins 54
5.2.2.2 Stringent regulatory scenario 54
5.2.3 OPPORTUNITIES 55
5.2.3.1 Emerging economies 55
5.2.3.2 Rising focus on personalized medicine and protein therapeutics 56
TABLE 2 COMMERCIALIZED RECOMBINANT PROTEINS USED IN MEDICINE 56
5.2.3.3 Increasing focus on biomarker discovery 57
5.2.4 CHALLENGES 57
5.2.4.1 Complications in large-scale production 57
5.3 PRICING ANALYSIS 58
5.3.1 AVERAGE SELLING PRICE OF PRODUCTS, BY KEY PLAYER 58
TABLE 3 PRICE OF RECOMBINANT PROTEINS, BY KEY PLAYER (USD) 58
5.3.2 AVERAGE SELLING PRICE TREND 58
TABLE 4 PRICE OF RECOMBINANT PROTEINS: INDUSTRIAL VS. PHARMACEUTICAL 59
5.4 STAKEHOLDER ANALYSIS 59
FIGURE 17 RECOMBINANT PROTEINS MARKET: STAKEHOLDER ANALYSIS 61
5.5 VALUE CHAIN ANALYSIS 61
FIGURE 18 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES 61
5.6 ECOSYSTEM ANALYSIS 62
FIGURE 19 BIOTECHNOLOGY ECOSYSTEM ANALYSIS: RECOMBINANT PROTEINS FORM AN INTEGRAL PART OF BIOTECHNOLOGY 62
5.7 REGULATORY ANALYSIS 63
5.7.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 63
TABLE 5 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 63
TABLE 6 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 63
TABLE 7 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 64
TABLE 8 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 64
5.8 PORTER’S FIVE FORCES ANALYSIS 65
TABLE 9 RECOMBINANT PROTEINS MARKET: PORTER’S FIVE FORCES ANALYSIS 65
5.8.1 THREAT OF NEW ENTRANTS 65
5.8.2 THREAT OF SUBSTITUTES 65
5.8.3 BARGAINING POWER OF BUYERS 66
5.8.4 BARGAINING POWER OF SUPPLIERS 66
5.8.5 INTENSITY OF RIVALRY 66
5.9 TECHNOLOGY ANALYSIS 67
5.10 PATENT ANALYSIS 68
FIGURE 20 TOP APPLICANTS AND OWNERS (COMPANIES/INSTITUTIONS) FOR RECOMBINANT PROTEIN PATENTS (JANUARY 2012–OCTOBER 2022) 68
TABLE 10 INDICATIVE LIST OF PATENTS IN RECOMBINANT PROTEINS MARKET 69
5.11 KEY CONFERENCES AND EVENTS IN 2022–2023 70
TABLE 11 RECOMBINANT PROTEINS MARKET: LIST OF CONFERENCES AND EVENTS 70
5.12 KEY STAKEHOLDERS AND BUYING CRITERIA 71
FIGURE 21 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS OF RECOMBINANT PROTEIN PRODUCTS 71
5.13 KEY BUYING CRITERIA OF END USERS 71
FIGURE 22 BUYING CRITERIA OF END USERS FOR RECOMBINANT PROTEINS 71
6 RECOMBINANT PROTEINS MARKET, BY PRODUCT 72
6.1 INTRODUCTION 73
6.2 GROWTH FACTORS AND CHEMOKINES 74
6.2.1 GROWTH FACTORS AND CHEMOKINES ACCOUNTED FOR LARGEST MARKET SHARE IN 2021 74
TABLE 13 GROWTH FACTORS AND CHEMOKINES MARKET, BY REGION, 2020–2027 (USD MILLION) 75
TABLE 14 NORTH AMERICA: GROWTH FACTORS AND CHEMOKINES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 75
TABLE 15 EUROPE: GROWTH FACTORS AND CHEMOKINES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 76
TABLE 16 ASIA PACIFIC: GROWTH FACTORS AND CHEMOKINES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 76
6.3 IMMUNE RESPONSE PROTEINS 77
6.3.1 IMMUNE CHECKPOINT PROTEINS PLAY KEY ROLE IN CANCER IMMUNOTHERAPY 77
TABLE 17 IMMUNE RESPONSE PROTEINS MARKET, BY REGION, 2020–2027 (USD MILLION) 77
TABLE 18 NORTH AMERICA: IMMUNE RESPONSE PROTEINS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 78
TABLE 19 EUROPE: IMMUNE RESPONSE PROTEINS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 78
TABLE 20 ASIA PACIFIC: IMMUNE RESPONSE PROTEINS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 78
6.4 STRUCTURAL PROTEINS 79
6.4.1 STRUCTURAL PROTEINS UTILIZED IN CELL CULTURE APPLICATIONS AS ATTACHMENT FACTORS 79
TABLE 21 STRUCTURAL PROTEINS MARKET, BY REGION, 2020–2027 (USD MILLION) 79
TABLE 22 NORTH AMERICA: STRUCTURAL PROTEINS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 80
TABLE 23 EUROPE: STRUCTURAL PROTEINS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 80
TABLE 24 ASIA PACIFIC: STRUCTURAL PROTEINS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 80
6.5 MEMBRANE PROTEINS 81
6.5.1 MEMBRANE PROTEINS REGULATE PROCESSES THAT HELP BIOLOGICAL CELLS SURVIVE 81
TABLE 25 MEMBRANE PROTEINS MARKET, BY REGION, 2020–2027 (USD MILLION) 81
TABLE 26 NORTH AMERICA: MEMBRANE PROTEINS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 82
TABLE 27 EUROPE: MEMBRANE PROTEINS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 82
TABLE 28 ASIA PACIFIC: MEMBRANE PROTEINS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 82
6.6 KINASE PROTEINS 83
6.6.1 KINASE PROTEINS PLAY KEY ROLE IN SIGNAL TRANSDUCTION PATHWAYS 83
TABLE 29 KINASE PROTEINS MARKET, BY REGION, 2020–2027 (USD MILLION) 83
TABLE 30 NORTH AMERICA: KINASE PROTEINS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 83
TABLE 31 EUROPE: KINASE PROTEINS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 84
TABLE 32 ASIA PACIFIC: KINASE PROTEINS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 84
6.7 REGULATORY PROTEINS 85
6.7.1 REGULATORY PROTEINS HELP UNDERSTAND CELL CYCLE REGULATION AND CARCINOGENESIS 85
TABLE 33 REGULATORY PROTEINS MARKET, BY REGION, 2020–2027 (USD MILLION) 85
TABLE 34 NORTH AMERICA: REGULATORY PROTEINS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 85
TABLE 35 EUROPE: REGULATORY PROTEINS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 86
TABLE 36 ASIA PACIFIC: REGULATORY PROTEINS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 86
6.8 RECOMBINANT METABOLIC ENZYMES 87
6.8.1 ENZYMES REGULATE PROTEIN INTERACTIONS 87
TABLE 37 RECOMBINANT METABOLIC ENZYMES MARKET, BY REGION, 2020–2027 (USD MILLION) 87
TABLE 38 NORTH AMERICA: RECOMBINANT METABOLIC ENZYMES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 87
TABLE 39 EUROPE: RECOMBINANT METABOLIC ENZYMES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 88
TABLE 40 ASIA PACIFIC: RECOMBINANT METABOLIC ENZYMES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 88
6.9 ADHESION MOLECULES AND RECEPTORS 89
6.9.1 CELL ADHESION MOLECULES FACILITATE EXTRACELLULAR MATRIX (ECM) INTERACTIONS 89
TABLE 41 ADHESION MOLECULES AND RECEPTORS MARKET, BY REGION, 2020–2027 (USD MILLION) 89
TABLE 42 NORTH AMERICA: ADHESION MOLECULES AND RECEPTORS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 89
TABLE 43 EUROPE: ADHESION MOLECULES AND RECEPTORS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 90
TABLE 44 ASIA PACIFIC: ADHESION MOLECULES AND RECEPTORS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 90
6.10 OTHER RECOMBINANT PROTEINS 91
TABLE 45 OTHER RECOMBINANT PROTEINS MARKET, BY REGION, 2020–2027 (USD MILLION) 91
TABLE 46 NORTH AMERICA: OTHER RECOMBINANT PROTEINS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 91
TABLE 47 EUROPE: OTHER RECOMBINANT PROTEINS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 92
TABLE 48 ASIA PACIFIC: OTHER RECOMBINANT PROTEINS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 92
7 RECOMBINANT PROTEINS MARKET, BY APPLICATION 93
7.1 INTRODUCTION 94
TABLE 49 RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 94
7.2 DRUG DISCOVERY AND DEVELOPMENT 94
TABLE 50 RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT, BY REGION, 2020–2027 (USD MILLION) 95
TABLE 51 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT, BY COUNTRY, 2020–2027 (USD MILLION) 95
TABLE 52 EUROPE: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT, BY COUNTRY, 2020–2027 (USD MILLION) 95
TABLE 53 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT, BY COUNTRY, 2020–2027 (USD MILLION) 96
TABLE 54 RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT, BY TYPE, 2020–2027 (USD MILLION) 96
7.2.1 BIOLOGICS 96
7.2.1.1 Biologics are used to treat cancer, autoimmune diseases, and other serious disorders 96
TABLE 55 RECOMBINANT PROTEIN BIOLOGIC DRUGS 97
TABLE 56 RECOMBINANT PROTEINS MARKET FOR BIOLOGICS, BY REGION, 2020–2027 (USD MILLION) 97
TABLE 57 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR BIOLOGICS, BY COUNTRY, 2020–2027 (USD MILLION) 98
TABLE 58 EUROPE: RECOMBINANT PROTEINS MARKET FOR BIOLOGICS, BY COUNTRY, 2020–2027 (USD MILLION) 98
TABLE 59 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR BIOLOGICS, BY COUNTRY, 2020–2027 (USD MILLION) 98
7.2.2 VACCINES 99
7.2.2.1 Rising incidence of infectious diseases to boost market growth for vaccines 99
TABLE 60 RECOMBINANT PROTEINS MARKET FOR VACCINES, BY REGION, 2020–2027 (USD MILLION) 99
TABLE 61 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR VACCINES, BY COUNTRY, 2020–2027 (USD MILLION) 100
TABLE 62 EUROPE: RECOMBINANT PROTEINS MARKET FOR VACCINES, BY COUNTRY, 2020–2027 (USD MILLION) 100
TABLE 63 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR VACCINES, BY COUNTRY, 2020–2027 (USD MILLION) 100
7.2.3 CELL AND GENE THERAPY 101
7.2.3.1 Stem cell therapy and CAR T-cell therapies have boosted demand for recombinant proteins 101
TABLE 64 RECOMBINANT PROTEINS MARKET FOR CELL AND GENE THERAPY, BY REGION, 2020–2027 (USD MILLION) 101
TABLE 65 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR CELL AND GENE THERAPY, BY COUNTRY, 2020–2027 (USD MILLION) 102
TABLE 66 EUROPE: RECOMBINANT PROTEINS MARKET FOR CELL AND GENE THERAPY, BY COUNTRY, 2020–2027 (USD MILLION) 102
TABLE 67 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR CELL AND GENE THERAPY, BY COUNTRY, 2020–2027 (USD MILLION) 102
7.3 ACADEMIC RESEARCH STUDIES 103
7.3.1 RECOMBINANT PROTEINS HAVE APPLICATIONS IN MOLECULAR AND GENE EXPRESSION STUDIES 103
TABLE 68 RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH STUDIES, BY REGION, 2020–2027 (USD MILLION) 103
TABLE 69 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH STUDIES, BY COUNTRY, 2020–2027 (USD MILLION) 104
TABLE 70 EUROPE: RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH STUDIES, BY COUNTRY, 2020–2027 (USD MILLION) 104
TABLE 71 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH STUDIES, BY COUNTRY, 2020–2027 (USD MILLION) 104
7.4 BIOPHARMACEUTICAL PRODUCTION 105
7.4.1 RECOMBINANT PROTEINS WIDELY USED FOR DEVELOPMENT OF PROTEIN-BASED DRUGS 105
TABLE 72 RECOMBINANT PROTEINS MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY REGION, 2020–2027 (USD MILLION) 105
TABLE 73 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY COUNTRY, 2020–2027 (USD MILLION) 105
TABLE 74 EUROPE: RECOMBINANT PROTEINS MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY COUNTRY, 2020–2027 (USD MILLION) 106
TABLE 75 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY COUNTRY, 2020–2027 (USD MILLION) 106
7.5 BIOTECHNOLOGY RESEARCH 106
7.5.1 INCREASING NUMBER OF RESEARCH PROJECTS IN GENOMICS TO DRIVE MARKET GROWTH 106
TABLE 76 RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY RESEARCH, BY REGION, 2020–2027 (USD MILLION) 107
TABLE 77 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY RESEARCH, BY COUNTRY, 2020–2027 (USD MILLION) 107
TABLE 78 EUROPE: RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY RESEARCH, BY COUNTRY, 2020–2027 (USD MILLION) 108
TABLE 79 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY RESEARCH, BY COUNTRY, 2020–2027 (USD MILLION) 108
7.6 DIAGNOSTICS 109
7.6.1 HIGH SENSITIVITY AND SPECIFICITY OF RECOMBINANT PROTEIN-BASED DIAGNOSTICS TO INFLUENCE MARKET GROWTH 109
TABLE 80 RECOMBINANT PROTEINS MARKET FOR DIAGNOSTICS, BY REGION, 2020–2027 (USD MILLION) 109
TABLE 81 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2020–2027 (USD MILLION) 109
TABLE 82 EUROPE: RECOMBINANT PROTEINS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2020–2027 (USD MILLION) 110
TABLE 83 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2020–2027 (USD MILLION) 110
7.7 OTHER APPLICATIONS 111
TABLE 84 RECOMBINANT PROTEINS MARKET FOR OTHER APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 111
TABLE 85 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 111
TABLE 86 EUROPE: RECOMBINANT PROTEINS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 112
TABLE 87 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 112
8 RECOMBINANT PROTEINS MARKET, BY END USER 113
8.1 INTRODUCTION 114
TABLE 88 RECOMBINANT PROTEINS MARKET, BY END USER, 2020–2027 (USD MILLION) 114
8.2 PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES 114
8.2.1 PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES ARE LARGEST END USERS OF RECOMBINANT PROTEINS 114
TABLE 89 RECOMBINANT PROTEINS MARKET FOR PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES, BY REGION, 2020–2027 (USD MILLION) 115
TABLE 90 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION) 115
TABLE 91 EUROPE: RECOMBINANT PROTEINS MARKET FOR PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION) 116
TABLE 92 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION) 116
8.3 BIOTECHNOLOGY COMPANIES 116
8.3.1 INCREASING NUMBER OF PROJECTS FOR PROTEIN-BASED RESEARCH DRIVING MARKET GROWTH 116
TABLE 93 RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY COMPANIES, BY REGION, 2020–2027 (USD MILLION) 117
TABLE 94 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION) 117
TABLE 95 EUROPE: RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION) 117
TABLE 96 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION) 118
8.4 ACADEMIC RESEARCH INSTITUTES 118
8.4.1 GROWING GOVERNMENT INVESTMENTS TO PROPEL MARKET GROWTH 118
TABLE 97 RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY REGION, 2020–2027 (USD MILLION) 119
TABLE 98 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION) 119
TABLE 99 EUROPE: RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION) 119
TABLE 100 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION) 120
8.5 CONTRACT RESEARCH ORGANIZATIONS 120
8.5.1 INCREASING OUTSOURCING OF SERVICES TO CROS DRIVING MARKET GROWTH 120
TABLE 101 RECOMBINANT PROTEINS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2020–2027 (USD MILLION) 121
TABLE 102 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 121
TABLE 103 EUROPE: RECOMBINANT PROTEINS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 121
TABLE 104 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 122
8.6 OTHER END USERS 122
TABLE 105 RECOMBINANT PROTEINS MARKET FOR OTHER END USERS, BY REGION, 2020–2027 (USD MILLION) 122
TABLE 106 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR OTHER END USERS, BY COUNTRY, 2020–2027 (USD MILLION) 123
TABLE 107 EUROPE: RECOMBINANT PROTEINS MARKET FOR OTHER END USERS, BY COUNTRY, 2020–2027 (USD MILLION) 123
TABLE 108 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR OTHER END USERS, BY COUNTRY, 2020–2027 (USD MILLION) 123
9 RECOMBINANT PROTEINS MARKET, BY REGION 124
9.1 INTRODUCTION 125
TABLE 109 RECOMBINANT PROTEINS MARKET, BY REGION, 2020–2027 (USD MILLION) 125
9.2 NORTH AMERICA 126
FIGURE 23 NORTH AMERICA: RECOMBINANT PROTEINS MARKET SNAPSHOT 126
TABLE 110 NORTH AMERICA: RECOMBINANT PROTEINS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 127
TABLE 111 NORTH AMERICA: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 127
TABLE 112 NORTH AMERICA: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 128
TABLE 114 NORTH AMERICA: RECOMBINANT PROTEINS MARKET, BY END USER, 2020–2027 (USD MILLION) 129
9.2.1 US 129
9.2.1.1 US accounted for largest share of North American market 129
TABLE 115 US NIH BUDGET FOR VARIOUS DISCIPLINES, FY 2020 VS. FY 2021 (USD BILLION) 130
TABLE 116 US: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 130
TABLE 117 US: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 131
TABLE 118 US: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 131
TABLE 119 US: RECOMBINANT PROTEINS MARKET, BY END USER, 2020–2027 (USD MILLION) 132
9.2.2 CANADA 132
9.2.2.1 High prevalence of cancer and favorable funding scenario to support market growth 132
TABLE 120 CANADA: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 133
TABLE 121 CANADA: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 134
TABLE 122 CANADA: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 134
TABLE 123 CANADA: RECOMBINANT PROTEINS MARKET, BY END USER, 2020–2027 (USD MILLION) 135
9.3 EUROPE 135
TABLE 124 EUROPE: RECOMBINANT PROTEINS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 136
TABLE 125 EUROPE: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 136
TABLE 126 EUROPE: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 137
TABLE 127 EUROPE: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 137
TABLE 128 EUROPE: RECOMBINANT PROTEINS MARKET, BY END USER, 2020–2027 (USD MILLION) 138
9.3.1 GERMANY 138
9.3.1.1 Germany held largest share of European market in 2021 138
TABLE 129 GERMANY: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 139
TABLE 130 GERMANY: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 139
TABLE 131 GERMANY: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 140
TABLE 132 GERMANY: RECOMBINANT PROTEINS MARKET, BY END USER, 2020–2027 (USD MILLION) 140
9.3.2 UK 140
9.3.2.1 Government initiatives to drive market growth in UK 140
TABLE 133 UK: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 141
TABLE 134 UK: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 142
TABLE 135 UK: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 142
TABLE 136 UK: RECOMBINANT PROTEINS MARKET, BY END USER, 2020–2027 (USD MILLION) 143
9.3.3 FRANCE 143
9.3.3.1 Infrastructural development and rising life science R&D expected to support market growth 143
TABLE 137 FRANCE: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 144
TABLE 138 FRANCE: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 145
TABLE 139 FRANCE: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 145
TABLE 140 FRANCE: RECOMBINANT PROTEINS MARKET, BY END USER, 2020–2027 (USD MILLION) 146
9.3.4 ITALY 146
9.3.4.1 Life science research investments and favorable funding scenario to drive growth 146
TABLE 141 ITALY: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 147
TABLE 142 ITALY: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 147
TABLE 143 ITALY: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 148
TABLE 144 ITALY: RECOMBINANT PROTEINS MARKET, BY END USER, 2020–2027 (USD MILLION) 148
9.3.5 SPAIN 148
9.3.5.1 Favorable scenario for research initiatives to propel market growth 148
TABLE 145 SPAIN: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 149
TABLE 146 SPAIN: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 150
TABLE 147 SPAIN: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 150
TABLE 148 SPAIN: RECOMBINANT PROTEINS MARKET, BY END USER, 2020–2027 (USD MILLION) 151
9.3.6 REST OF EUROPE 151
TABLE 149 ROE: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 152
TABLE 150 ROE: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 152
TABLE 151 ROE: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 153
TABLE 152 ROE: RECOMBINANT PROTEINS MARKET, BY END USER, 2020–2027 (USD MILLION) 153
9.4 ASIA PACIFIC 154
TABLE 153 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 156
TABLE 154 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 156
TABLE 155 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 157
TABLE 156 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 157
TABLE 157 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET, BY END USER, 2020–2027 (USD MILLION) 158
9.4.1 JAPAN 158
9.4.1.1 Advanced healthcare infrastructure to support market growth 158
TABLE 158 JAPAN: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 159
TABLE 159 JAPAN: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 159
TABLE 160 JAPAN: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 160
TABLE 161 JAPAN: RECOMBINANT PROTEINS MARKET, BY END USER, 2020–2027 (USD MILLION) 160
9.4.2 CHINA 160
9.4.2.1 China to witness highest growth in Asia Pacific market 160
TABLE 162 CHINA: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 161
TABLE 163 CHINA: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 162
TABLE 164 CHINA: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 162
TABLE 165 CHINA: RECOMBINANT PROTEINS MARKET, BY END USER, 2020–2027 (USD MILLION) 163
9.4.3 INDIA 163
9.4.3.1 Strong biopharmaceutical growth and rising demand for pharmaceuticals are key market drivers 163
TABLE 166 INDIA: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 164
TABLE 167 INDIA: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 165
TABLE 168 INDIA: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 165
TABLE 169 INDIA: RECOMBINANT PROTEINS MARKET, BY END USER, 2020–2027 (USD MILLION) 166
9.4.4 REST OF ASIA PACIFIC 166
TABLE 170 ROAPAC: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 167
TABLE 171 ROAPAC: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 168
TABLE 172 ROAPAC: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 168
TABLE 173 ROAPAC: RECOMBINANT PROTEINS MARKET, BY END USER, 2020–2027 (USD MILLION) 169
9.5 LATIN AMERICA 169
9.5.1 GROWTH IN BIOPHARMACEUTICAL INDUSTRY TO DRIVE DEMAND FOR RECOMBINANT PROTEINS 169
TABLE 174 LATIN AMERICA: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 170
TABLE 175 LATIN AMERICA: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 171
TABLE 176 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 171
TABLE 177 LATIN AMERICA: RECOMBINANT PROTEINS MARKET, BY END USER, 2020–2027 (USD MILLION) 172
9.6 MIDDLE EAST & AFRICA 172
9.6.1 INCREASING GOVERNMENT INVESTMENTS IN HEALTHCARE SECTOR AND GROWING PHARMACEUTICAL INDUSTRY TO SUPPORT MARKET GROWTH 172
TABLE 178 MIDDLE EAST & AFRICA: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 173
TABLE 179 MIDDLE EAST & AFRICA: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 174
TABLE 180 MIDDLE EAST & AFRICA: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 174
TABLE 181 MIDDLE EAST & AFRICA: RECOMBINANT PROTEINS MARKET, BY END USER, 2020–2027 (USD MILLION) 175
 
10 COMPETITIVE LANDSCAPE 176
10.1 OVERVIEW 176
FIGURE 25 KEY PLAYERS ADOPTED ORGANIC AND INORGANIC GROWTH STRATEGIES BETWEEN 2019 AND 2022 176
10.2 MARKET SHARE ANALYSIS 177
FIGURE 26 RECOMBINANT PROTEINS MARKET: MARKET SHARE ANALYSIS, 2021 (TOP 4 PLAYERS) 177
TABLE 182 RECOMBINANT PROTEINS MARKET: DEGREE OF COMPETITION 178
10.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS 179
FIGURE 27 REVENUE SHARE ANALYSIS OF PLAYERS IN RECOMBINANT PROTEINS MARKET (TOP 4) 179
10.4 COMPANY EVALUATION MATRIX: KEY PLAYERS (2021) 180
10.4.1 VENDOR INCLUSION CRITERIA 180
10.4.2 STARS 180
10.4.3 EMERGING LEADERS 180
10.4.4 PERVASIVE PLAYERS 180
10.4.5 PARTICIPANTS 180
FIGURE 28 RECOMBINANT PROTEINS MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS (2021) 181
10.5 COMPANY EVALUATION MATRIX: START-UPS/SMES (2021) 182
10.5.1 PROGRESSIVE COMPANIES 182
10.5.2 STARTING BLOCKS 182
10.5.3 RESPONSIVE COMPANIES 182
10.5.4 DYNAMIC COMPANIES 182
FIGURE 29 RECOMBINANT PROTEINS MARKET: COMPANY EVALUATION MATRIX FOR START-UPS/SMES (2021) 183
10.6 COMPETITIVE BENCHMARKING OF TOP 25 COMPANIES 184
10.6.1 OVERALL FOOTPRINT OF TOP 25 COMPANIES 184
FIGURE 30 FOOTPRINT ANALYSIS OF KEY PLAYERS IN RECOMBINANT PROTEINS MARKET 184
10.7 COMPETITIVE BENCHMARKING OF KEY START-UPS/SMES 185
TABLE 183 RECOMBINANT PROTEINS MARKET: DETAILED LIST OF KEY START-UPS/SMES 185
TABLE 184 RECOMBINANT PROTEINS MARKET: COMPETITIVE BENCHMARKING OF KEY START-UPS/SMES 186
10.8 COMPETITIVE SCENARIO 186
10.8.1 PRODUCT LAUNCHES AND APPROVALS (2019–2022) 186
10.8.2 DEALS (2019–2022) 187
10.8.3 EXPANSIONS (2019–2022) 188
 
11 COMPANY PROFILES 189
11.1 KEY PLAYERS 189
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
11.1.1 BIO-TECHNE CORPORATION 189
TABLE 185 R&D SYSTEMS: BUSINESS OVERVIEW 189
FIGURE 31 BIO‑TECHNE CORPORATION: COMPANY SNAPSHOT (2021) 190
11.1.2 THERMO FISHER SCIENTIFIC, INC. 194
TABLE 186 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW 194
FIGURE 32 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2021) 195
11.1.3 MERCK KGAA 198
TABLE 187 MERCK KGAA: BUSINESS OVERVIEW 198
FIGURE 33 MERCK KGAA: COMPANY SNAPSHOT (2021) 199
11.1.4 ABCAM PLC 202
TABLE 188 ABCAM PLC: BUSINESS OVERVIEW 202
FIGURE 34 ABCAM PLC: COMPANY SNAPSHOT (2021) 202
11.1.5 ABNOVA CORPORATION 205
TABLE 189 ABNOVA CORPORATION: BUSINESS OVERVIEW 205
11.1.6 BIOLEGEND 207
TABLE 190 BIOLEGEND: BUSINESS OVERVIEW 207
11.1.7 BIO-RAD LABORATORIES, INC. 209
TABLE 191 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW 209
FIGURE 35 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2021) 210
11.1.8 BPS BIOSCIENCE, INC. 211
TABLE 192 BPS BIOSCIENCE, INC.: BUSINESS OVERVIEW 211
11.1.9 ENZO LIFE SCIENCES, INC. 213
TABLE 193 ENZO LIFE SCIENCES, INC.: BUSINESS OVERVIEW 213
FIGURE 36 ENZO BIOCHEM, INC.: COMPANY SNAPSHOT (2021) 214
11.1.10 GENSCRIPT BIOTECH CORPORATION 216
FIGURE 37 GENSCRIPT BIOTECH CORPORATION: COMPANY SNAPSHOT (2021) 217
11.1.11 MILTENYI BIOTEC 220
TABLE 195 MILTENYI BIOTECH: BUSINESS OVERVIEW 220
11.1.12 PROTEINTECH GROUP 222
TABLE 196 PROTEINTECH GROUP: BUSINESS OVERVIEW 222
11.1.13 SINO BIOLOGICAL INC. 224
TABLE 197 SINO BIOLOGICAL INC.: BUSINESS OVERVIEW 224
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
11.2 OTHER PLAYERS 227
11.2.1 ACROBIOSYSTEMS 227
11.2.2 AVIVA SYSTEMS BIOLOGY CORPORATION 228
11.2.3 CELLGENIX GMBH 228
11.2.4 ICOSAGEN AS 229
11.2.5 NEUROMICS 230
11.2.6 PROSPEC-TECHNOGENE LTD. 231
11.2.7 PROTEOGENIX 232
11.2.8 RAYBIOTECH, INC. 233
11.2.9 LAURUS BIO (RICHCORE LIFESCIENCES PVT. LTD.) 234
11.2.10 STEMCELL TECHNOLOGIES INC. 235
11.2.11 STRESSMARQ BIOSCIENCES INC. 236
11.2.12 UNITED STATES BIOLOGICAL 237
12 APPENDIX 238
12.1 DISCUSSION GUIDE 238
12.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 242
12.3 CUSTOMIZATION OPTIONS 244
12.4 RELATED REPORTS 244
12.5 AUTHOR DETAILS 245

　

ページTOPに戻る


　

Summary

The global recombinant proteins market is projected to reach USD 2.4 billion by 2027 from USD 1.4 billion in 2022, at a CAGR of 11.4% during the forecast period. The market growth is primarily driven by factors such as increasing government investments and R&D expenditure in pharmaceutical & biotechnology companies and academic research institutes alongside the high prevalence of chronic and infectious diseases resulting in the need for recombinant proteins for crucial diagnostics. However, flocking to the market with competitively priced products and labor-intensive processes with low yields of recombinant protein may restrict market growth to a certain extent


“The pharmaceutical & biopharmaceutical companies segment is expected to dominate the market during the forecast period.”
Based on end users, the recombinant proteins market is segmented into pharmaceutical & biopharmaceutical companies, biotechnology companies, academic research institutes, contract research organizations, and other end users. Pharmaceutical & biopharmaceutical companies accounted for the largest share of the end user market in 2020. The large share of this segment is attributed to the role of recombinant proteins as a crucial component of most small molecule drug discovery programs, as well as the requirement of recombinant protein in drug discovery for the screening of the structural and mechanistic studies of new drug applications. Also, factors such as the patent expiration of blockbuster drugs impact the market growth positively.


“Vaccine segment will witness the second highest growth in the recombinant proteins market during the forecast period.”

Based on type, the drug discovery & development market is segmented into biologics, vaccines, and cell & gene therapy.Vaccine accounted for the second largest share of the drug discovery & development application for the recombinant proteins market and is expected to register the second highest CAGR during the forecast period. The large share of the vaccine segment is attributed to the factors such increased incidence of diseases such as influenza, viral diseases and hepatitis. The emergence of such diseases has led to increased R&D activities to discover proactive vaccine and this is fueling the market growth for recombinant protein.

“North America will dominate the market during the forecast period.”
Geographically, the recombinant proteins market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2021, North America accounted for the largest share of the recombinant proteins market. The large share of this region in the global market is attributed to the rising prevalence of infectious diseases and chronic conditions, growing R&D spending by the government and pharmaceutical industry, increasing research activities by biotechnology firms, and the presence of key market players.




The primary interviews conducted for this report can be categorized as follows:

• By Company Type - Tier 1: 36%, Tier 2: 45%, and Tier 3: 19%
• By Designation - C-level: 33%, D-level: 40%, and Others: 27%
• By Region - North America: 36%, Europe: 28%, Asia Pacific: 19%, Latin America: 10%, and Middle East and Africa 7%.

List of Companies Profiled in the Report
• Thermo Fisher Scientific Inc. (US)
• Miltenyi Biotech (Germany)
• Sino Biological Inc. (China)
• Merck KGaA (Germany)
• Abcam plc (UK)
• Biolegend (US)
• Bio-Rad Laboratories, Inc. (US)
• GenScript Biotech Corporation (China)
• Enzo Life Sciences, Inc. (US)
• BPS Bioscience, Inc. (US)
• Proteintech Group, Inc. (US)
• Abnova Corporation (Taiwan)
• R&D Systems (US)
• STEMCELL Technologies Inc (Canada)
• RayBiotech Inc (US)
• CellGenix GmbH (Germany)
• ACROBiosystems (US)
• ProSpec-TechnoGene Ltd. (Israel)
• Neuromics (US)
• Lauraus Bio (India)
• Icosagen AS (US)
• ProteoGenix (France)
• United States Biological (US)
• StressMarq Biosciences Inc (Canada)
• Aviva Systems Biology Corporation (US)





Research Coverage:
This report provides a detailed picture of the global recombinant proteins market. It aims at estimating the size and future growth potential of the market across different segments, such as product, application, end user, and region. The report also analyzes factors (such as drivers, restraints, challenges, and opportunities) affecting the market growth. It evaluates the opportunities in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micromarkets with respect to their growth trends, prospects, and contributions to the total recombinant proteins market. The report forecasts the revenue of the market segments with respect to five major regions.

Reasons to Buy the Report:
The report provides insights on the following pointers:
• Market Penetration: Comprehensive information on recombinant proteins offered by the top 25 players in the recombinant proteins market. The report analyses the recombinant proteins market by product, application, end user, and region.

• Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various recombinant proteins across key geographic regions.

• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the recombinant proteins market.

• Competitive Assessment: In-depth assessment of market ranking and strategies of the leading players in the recombinant proteins market.



ページTOPに戻る


Table of Contents

1 INTRODUCTION 32
1.1 STUDY OBJECTIVES 32
1.2 MARKET DEFINITION 32
1.2.1 INCLUSIONS AND EXCLUSIONS 33
1.3 MARKET SCOPE 34
FIGURE 1 RECOMBINANT PROTEINS MARKET 34
1.4 YEARS CONSIDERED 35
1.5 CURRENCY CONSIDERED 35
1.6 LIMITATIONS 35
1.7 STAKEHOLDERS 35
1.8 SUMMARY OF CHANGES 36
2 RESEARCH METHODOLOGY 37
2.1 RESEARCH DATA 37
FIGURE 2 RESEARCH DESIGN 37
2.1.1 SECONDARY DATA 38
2.1.1.1 Secondary sources 38
2.1.2 PRIMARY DATA 38
2.1.2.1 Key data from primary sources 39
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 39
2.2 MARKET SIZE ESTIMATION 40
2.2.1 BOTTOM-UP APPROACH 40
FIGURE 4 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH 40
2.2.2 TOP-DOWN APPROACH 41
FIGURE 5 MARKET SIZE ESTIMATION: TOP-DOWN APPROACH 41
2.2.3 GROWTH FORECAST 41
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 42
FIGURE 6 DATA TRIANGULATION METHODOLOGY 42
2.4 ASSUMPTIONS 43
3 EXECUTIVE SUMMARY 44
FIGURE 7 RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2022 VS. 2027 (USD MILLION) 44
FIGURE 8 RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION) 45
FIGURE 9 RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT APPLICATIONS, BY TYPE, 2022–2027 (USD MILLION) 45
FIGURE 10 RECOMBINANT PROTEINS MARKET, BY END USER, 2022 VS. 2027 (USD MILLION) 46
4 PREMIUM INSIGHTS 48
4.1 RECOMBINANT PROTEINS MARKET OVERVIEW 48
FIGURE 12 INCREASING GOVERNMENT INVESTMENTS AND RISING FOCUS ON PERSONALIZED MEDICINE TO DRIVE MARKET GROWTH 48
4.2 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET, BY APPLICATION AND COUNTRY (2022) 49
FIGURE 13 DRUG DISCOVERY AND DEVELOPMENT SEGMENT TO ACCOUNT FOR LARGEST SHARE IN ASIA PACIFIC MARKET 49
4.3 RECOMBINANT PROTEINS MARKET, BY END USER, 2022–2027 50
FIGURE 14 PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES TO FORM LARGEST END-USER SEGMENT FOR RECOMBINANT PROTEINS 50
4.4 RECOMBINANT PROTEINS MARKET: GEOGRAPHIC SNAPSHOT 50
FIGURE 15 JAPAN TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 50
5 MARKET OVERVIEW 51
5.1 INTRODUCTION 51
5.2 MARKET DYNAMICS 51
FIGURE 16 RECOMBINANT PROTEINS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 51
5.2.1 DRIVERS 52
5.2.1.1 Rising government funding and increasing R&D expenditure in pharmaceutical and biotechnology companies 52
TABLE 1 GOVERNMENT FUNDING FOR LIFE SCIENCE RESEARCH (2022) 52
5.2.1.2 High prevalence of infectious and chronic diseases 53
5.2.1.3 Growing industry-academia collaborations 53
5.2.1.4 Patent expiry of biologics 54
5.2.2 RESTRAINTS 54
5.2.2.1 Declining cost of recombinant proteins 54
5.2.2.2 Stringent regulatory scenario 54
5.2.3 OPPORTUNITIES 55
5.2.3.1 Emerging economies 55
5.2.3.2 Rising focus on personalized medicine and protein therapeutics 56
TABLE 2 COMMERCIALIZED RECOMBINANT PROTEINS USED IN MEDICINE 56
5.2.3.3 Increasing focus on biomarker discovery 57
5.2.4 CHALLENGES 57
5.2.4.1 Complications in large-scale production 57
5.3 PRICING ANALYSIS 58
5.3.1 AVERAGE SELLING PRICE OF PRODUCTS, BY KEY PLAYER 58
TABLE 3 PRICE OF RECOMBINANT PROTEINS, BY KEY PLAYER (USD) 58
5.3.2 AVERAGE SELLING PRICE TREND 58
TABLE 4 PRICE OF RECOMBINANT PROTEINS: INDUSTRIAL VS. PHARMACEUTICAL 59
5.4 STAKEHOLDER ANALYSIS 59
FIGURE 17 RECOMBINANT PROTEINS MARKET: STAKEHOLDER ANALYSIS 61
5.5 VALUE CHAIN ANALYSIS 61
FIGURE 18 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES 61
5.6 ECOSYSTEM ANALYSIS 62
FIGURE 19 BIOTECHNOLOGY ECOSYSTEM ANALYSIS: RECOMBINANT PROTEINS FORM AN INTEGRAL PART OF BIOTECHNOLOGY 62
5.7 REGULATORY ANALYSIS 63
5.7.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 63
TABLE 5 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 63
TABLE 6 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 63
TABLE 7 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 64
TABLE 8 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 64
5.8 PORTER’S FIVE FORCES ANALYSIS 65
TABLE 9 RECOMBINANT PROTEINS MARKET: PORTER’S FIVE FORCES ANALYSIS 65
5.8.1 THREAT OF NEW ENTRANTS 65
5.8.2 THREAT OF SUBSTITUTES 65
5.8.3 BARGAINING POWER OF BUYERS 66
5.8.4 BARGAINING POWER OF SUPPLIERS 66
5.8.5 INTENSITY OF RIVALRY 66
5.9 TECHNOLOGY ANALYSIS 67
5.10 PATENT ANALYSIS 68
FIGURE 20 TOP APPLICANTS AND OWNERS (COMPANIES/INSTITUTIONS) FOR RECOMBINANT PROTEIN PATENTS (JANUARY 2012–OCTOBER 2022) 68
TABLE 10 INDICATIVE LIST OF PATENTS IN RECOMBINANT PROTEINS MARKET 69
5.11 KEY CONFERENCES AND EVENTS IN 2022–2023 70
TABLE 11 RECOMBINANT PROTEINS MARKET: LIST OF CONFERENCES AND EVENTS 70
5.12 KEY STAKEHOLDERS AND BUYING CRITERIA 71
FIGURE 21 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS OF RECOMBINANT PROTEIN PRODUCTS 71
5.13 KEY BUYING CRITERIA OF END USERS 71
FIGURE 22 BUYING CRITERIA OF END USERS FOR RECOMBINANT PROTEINS 71
6 RECOMBINANT PROTEINS MARKET, BY PRODUCT 72
6.1 INTRODUCTION 73
6.2 GROWTH FACTORS AND CHEMOKINES 74
6.2.1 GROWTH FACTORS AND CHEMOKINES ACCOUNTED FOR LARGEST MARKET SHARE IN 2021 74
TABLE 13 GROWTH FACTORS AND CHEMOKINES MARKET, BY REGION, 2020–2027 (USD MILLION) 75
TABLE 14 NORTH AMERICA: GROWTH FACTORS AND CHEMOKINES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 75
TABLE 15 EUROPE: GROWTH FACTORS AND CHEMOKINES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 76
TABLE 16 ASIA PACIFIC: GROWTH FACTORS AND CHEMOKINES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 76
6.3 IMMUNE RESPONSE PROTEINS 77
6.3.1 IMMUNE CHECKPOINT PROTEINS PLAY KEY ROLE IN CANCER IMMUNOTHERAPY 77
TABLE 17 IMMUNE RESPONSE PROTEINS MARKET, BY REGION, 2020–2027 (USD MILLION) 77
TABLE 18 NORTH AMERICA: IMMUNE RESPONSE PROTEINS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 78
TABLE 19 EUROPE: IMMUNE RESPONSE PROTEINS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 78
TABLE 20 ASIA PACIFIC: IMMUNE RESPONSE PROTEINS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 78
6.4 STRUCTURAL PROTEINS 79
6.4.1 STRUCTURAL PROTEINS UTILIZED IN CELL CULTURE APPLICATIONS AS ATTACHMENT FACTORS 79
TABLE 21 STRUCTURAL PROTEINS MARKET, BY REGION, 2020–2027 (USD MILLION) 79
TABLE 22 NORTH AMERICA: STRUCTURAL PROTEINS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 80
TABLE 23 EUROPE: STRUCTURAL PROTEINS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 80
TABLE 24 ASIA PACIFIC: STRUCTURAL PROTEINS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 80
6.5 MEMBRANE PROTEINS 81
6.5.1 MEMBRANE PROTEINS REGULATE PROCESSES THAT HELP BIOLOGICAL CELLS SURVIVE 81
TABLE 25 MEMBRANE PROTEINS MARKET, BY REGION, 2020–2027 (USD MILLION) 81
TABLE 26 NORTH AMERICA: MEMBRANE PROTEINS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 82
TABLE 27 EUROPE: MEMBRANE PROTEINS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 82
TABLE 28 ASIA PACIFIC: MEMBRANE PROTEINS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 82
6.6 KINASE PROTEINS 83
6.6.1 KINASE PROTEINS PLAY KEY ROLE IN SIGNAL TRANSDUCTION PATHWAYS 83
TABLE 29 KINASE PROTEINS MARKET, BY REGION, 2020–2027 (USD MILLION) 83
TABLE 30 NORTH AMERICA: KINASE PROTEINS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 83
TABLE 31 EUROPE: KINASE PROTEINS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 84
TABLE 32 ASIA PACIFIC: KINASE PROTEINS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 84
6.7 REGULATORY PROTEINS 85
6.7.1 REGULATORY PROTEINS HELP UNDERSTAND CELL CYCLE REGULATION AND CARCINOGENESIS 85
TABLE 33 REGULATORY PROTEINS MARKET, BY REGION, 2020–2027 (USD MILLION) 85
TABLE 34 NORTH AMERICA: REGULATORY PROTEINS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 85
TABLE 35 EUROPE: REGULATORY PROTEINS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 86
TABLE 36 ASIA PACIFIC: REGULATORY PROTEINS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 86
6.8 RECOMBINANT METABOLIC ENZYMES 87
6.8.1 ENZYMES REGULATE PROTEIN INTERACTIONS 87
TABLE 37 RECOMBINANT METABOLIC ENZYMES MARKET, BY REGION, 2020–2027 (USD MILLION) 87
TABLE 38 NORTH AMERICA: RECOMBINANT METABOLIC ENZYMES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 87
TABLE 39 EUROPE: RECOMBINANT METABOLIC ENZYMES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 88
TABLE 40 ASIA PACIFIC: RECOMBINANT METABOLIC ENZYMES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 88
6.9 ADHESION MOLECULES AND RECEPTORS 89
6.9.1 CELL ADHESION MOLECULES FACILITATE EXTRACELLULAR MATRIX (ECM) INTERACTIONS 89
TABLE 41 ADHESION MOLECULES AND RECEPTORS MARKET, BY REGION, 2020–2027 (USD MILLION) 89
TABLE 42 NORTH AMERICA: ADHESION MOLECULES AND RECEPTORS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 89
TABLE 43 EUROPE: ADHESION MOLECULES AND RECEPTORS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 90
TABLE 44 ASIA PACIFIC: ADHESION MOLECULES AND RECEPTORS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 90
6.10 OTHER RECOMBINANT PROTEINS 91
TABLE 45 OTHER RECOMBINANT PROTEINS MARKET, BY REGION, 2020–2027 (USD MILLION) 91
TABLE 46 NORTH AMERICA: OTHER RECOMBINANT PROTEINS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 91
TABLE 47 EUROPE: OTHER RECOMBINANT PROTEINS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 92
TABLE 48 ASIA PACIFIC: OTHER RECOMBINANT PROTEINS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 92
7 RECOMBINANT PROTEINS MARKET, BY APPLICATION 93
7.1 INTRODUCTION 94
TABLE 49 RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 94
7.2 DRUG DISCOVERY AND DEVELOPMENT 94
TABLE 50 RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT, BY REGION, 2020–2027 (USD MILLION) 95
TABLE 51 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT, BY COUNTRY, 2020–2027 (USD MILLION) 95
TABLE 52 EUROPE: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT, BY COUNTRY, 2020–2027 (USD MILLION) 95
TABLE 53 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT, BY COUNTRY, 2020–2027 (USD MILLION) 96
TABLE 54 RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT, BY TYPE, 2020–2027 (USD MILLION) 96
7.2.1 BIOLOGICS 96
7.2.1.1 Biologics are used to treat cancer, autoimmune diseases, and other serious disorders 96
TABLE 55 RECOMBINANT PROTEIN BIOLOGIC DRUGS 97
TABLE 56 RECOMBINANT PROTEINS MARKET FOR BIOLOGICS, BY REGION, 2020–2027 (USD MILLION) 97
TABLE 57 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR BIOLOGICS, BY COUNTRY, 2020–2027 (USD MILLION) 98
TABLE 58 EUROPE: RECOMBINANT PROTEINS MARKET FOR BIOLOGICS, BY COUNTRY, 2020–2027 (USD MILLION) 98
TABLE 59 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR BIOLOGICS, BY COUNTRY, 2020–2027 (USD MILLION) 98
7.2.2 VACCINES 99
7.2.2.1 Rising incidence of infectious diseases to boost market growth for vaccines 99
TABLE 60 RECOMBINANT PROTEINS MARKET FOR VACCINES, BY REGION, 2020–2027 (USD MILLION) 99
TABLE 61 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR VACCINES, BY COUNTRY, 2020–2027 (USD MILLION) 100
TABLE 62 EUROPE: RECOMBINANT PROTEINS MARKET FOR VACCINES, BY COUNTRY, 2020–2027 (USD MILLION) 100
TABLE 63 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR VACCINES, BY COUNTRY, 2020–2027 (USD MILLION) 100
7.2.3 CELL AND GENE THERAPY 101
7.2.3.1 Stem cell therapy and CAR T-cell therapies have boosted demand for recombinant proteins 101
TABLE 64 RECOMBINANT PROTEINS MARKET FOR CELL AND GENE THERAPY, BY REGION, 2020–2027 (USD MILLION) 101
TABLE 65 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR CELL AND GENE THERAPY, BY COUNTRY, 2020–2027 (USD MILLION) 102
TABLE 66 EUROPE: RECOMBINANT PROTEINS MARKET FOR CELL AND GENE THERAPY, BY COUNTRY, 2020–2027 (USD MILLION) 102
TABLE 67 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR CELL AND GENE THERAPY, BY COUNTRY, 2020–2027 (USD MILLION) 102
7.3 ACADEMIC RESEARCH STUDIES 103
7.3.1 RECOMBINANT PROTEINS HAVE APPLICATIONS IN MOLECULAR AND GENE EXPRESSION STUDIES 103
TABLE 68 RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH STUDIES, BY REGION, 2020–2027 (USD MILLION) 103
TABLE 69 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH STUDIES, BY COUNTRY, 2020–2027 (USD MILLION) 104
TABLE 70 EUROPE: RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH STUDIES, BY COUNTRY, 2020–2027 (USD MILLION) 104
TABLE 71 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH STUDIES, BY COUNTRY, 2020–2027 (USD MILLION) 104
7.4 BIOPHARMACEUTICAL PRODUCTION 105
7.4.1 RECOMBINANT PROTEINS WIDELY USED FOR DEVELOPMENT OF PROTEIN-BASED DRUGS 105
TABLE 72 RECOMBINANT PROTEINS MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY REGION, 2020–2027 (USD MILLION) 105
TABLE 73 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY COUNTRY, 2020–2027 (USD MILLION) 105
TABLE 74 EUROPE: RECOMBINANT PROTEINS MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY COUNTRY, 2020–2027 (USD MILLION) 106
TABLE 75 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY COUNTRY, 2020–2027 (USD MILLION) 106
7.5 BIOTECHNOLOGY RESEARCH 106
7.5.1 INCREASING NUMBER OF RESEARCH PROJECTS IN GENOMICS TO DRIVE MARKET GROWTH 106
TABLE 76 RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY RESEARCH, BY REGION, 2020–2027 (USD MILLION) 107
TABLE 77 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY RESEARCH, BY COUNTRY, 2020–2027 (USD MILLION) 107
TABLE 78 EUROPE: RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY RESEARCH, BY COUNTRY, 2020–2027 (USD MILLION) 108
TABLE 79 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY RESEARCH, BY COUNTRY, 2020–2027 (USD MILLION) 108
7.6 DIAGNOSTICS 109
7.6.1 HIGH SENSITIVITY AND SPECIFICITY OF RECOMBINANT PROTEIN-BASED DIAGNOSTICS TO INFLUENCE MARKET GROWTH 109
TABLE 80 RECOMBINANT PROTEINS MARKET FOR DIAGNOSTICS, BY REGION, 2020–2027 (USD MILLION) 109
TABLE 81 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2020–2027 (USD MILLION) 109
TABLE 82 EUROPE: RECOMBINANT PROTEINS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2020–2027 (USD MILLION) 110
TABLE 83 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2020–2027 (USD MILLION) 110
7.7 OTHER APPLICATIONS 111
TABLE 84 RECOMBINANT PROTEINS MARKET FOR OTHER APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 111
TABLE 85 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 111
TABLE 86 EUROPE: RECOMBINANT PROTEINS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 112
TABLE 87 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 112
8 RECOMBINANT PROTEINS MARKET, BY END USER 113
8.1 INTRODUCTION 114
TABLE 88 RECOMBINANT PROTEINS MARKET, BY END USER, 2020–2027 (USD MILLION) 114
8.2 PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES 114
8.2.1 PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES ARE LARGEST END USERS OF RECOMBINANT PROTEINS 114
TABLE 89 RECOMBINANT PROTEINS MARKET FOR PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES, BY REGION, 2020–2027 (USD MILLION) 115
TABLE 90 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION) 115
TABLE 91 EUROPE: RECOMBINANT PROTEINS MARKET FOR PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION) 116
TABLE 92 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION) 116
8.3 BIOTECHNOLOGY COMPANIES 116
8.3.1 INCREASING NUMBER OF PROJECTS FOR PROTEIN-BASED RESEARCH DRIVING MARKET GROWTH 116
TABLE 93 RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY COMPANIES, BY REGION, 2020–2027 (USD MILLION) 117
TABLE 94 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION) 117
TABLE 95 EUROPE: RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION) 117
TABLE 96 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION) 118
8.4 ACADEMIC RESEARCH INSTITUTES 118
8.4.1 GROWING GOVERNMENT INVESTMENTS TO PROPEL MARKET GROWTH 118
TABLE 97 RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY REGION, 2020–2027 (USD MILLION) 119
TABLE 98 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION) 119
TABLE 99 EUROPE: RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION) 119
TABLE 100 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION) 120
8.5 CONTRACT RESEARCH ORGANIZATIONS 120
8.5.1 INCREASING OUTSOURCING OF SERVICES TO CROS DRIVING MARKET GROWTH 120
TABLE 101 RECOMBINANT PROTEINS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2020–2027 (USD MILLION) 121
TABLE 102 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 121
TABLE 103 EUROPE: RECOMBINANT PROTEINS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 121
TABLE 104 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 122
8.6 OTHER END USERS 122
TABLE 105 RECOMBINANT PROTEINS MARKET FOR OTHER END USERS, BY REGION, 2020–2027 (USD MILLION) 122
TABLE 106 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR OTHER END USERS, BY COUNTRY, 2020–2027 (USD MILLION) 123
TABLE 107 EUROPE: RECOMBINANT PROTEINS MARKET FOR OTHER END USERS, BY COUNTRY, 2020–2027 (USD MILLION) 123
TABLE 108 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR OTHER END USERS, BY COUNTRY, 2020–2027 (USD MILLION) 123
9 RECOMBINANT PROTEINS MARKET, BY REGION 124
9.1 INTRODUCTION 125
TABLE 109 RECOMBINANT PROTEINS MARKET, BY REGION, 2020–2027 (USD MILLION) 125
9.2 NORTH AMERICA 126
FIGURE 23 NORTH AMERICA: RECOMBINANT PROTEINS MARKET SNAPSHOT 126
TABLE 110 NORTH AMERICA: RECOMBINANT PROTEINS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 127
TABLE 111 NORTH AMERICA: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 127
TABLE 112 NORTH AMERICA: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 128
TABLE 114 NORTH AMERICA: RECOMBINANT PROTEINS MARKET, BY END USER, 2020–2027 (USD MILLION) 129
9.2.1 US 129
9.2.1.1 US accounted for largest share of North American market 129
TABLE 115 US NIH BUDGET FOR VARIOUS DISCIPLINES, FY 2020 VS. FY 2021 (USD BILLION) 130
TABLE 116 US: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 130
TABLE 117 US: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 131
TABLE 118 US: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 131
TABLE 119 US: RECOMBINANT PROTEINS MARKET, BY END USER, 2020–2027 (USD MILLION) 132
9.2.2 CANADA 132
9.2.2.1 High prevalence of cancer and favorable funding scenario to support market growth 132
TABLE 120 CANADA: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 133
TABLE 121 CANADA: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 134
TABLE 122 CANADA: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 134
TABLE 123 CANADA: RECOMBINANT PROTEINS MARKET, BY END USER, 2020–2027 (USD MILLION) 135
9.3 EUROPE 135
TABLE 124 EUROPE: RECOMBINANT PROTEINS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 136
TABLE 125 EUROPE: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 136
TABLE 126 EUROPE: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 137
TABLE 127 EUROPE: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 137
TABLE 128 EUROPE: RECOMBINANT PROTEINS MARKET, BY END USER, 2020–2027 (USD MILLION) 138
9.3.1 GERMANY 138
9.3.1.1 Germany held largest share of European market in 2021 138
TABLE 129 GERMANY: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 139
TABLE 130 GERMANY: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 139
TABLE 131 GERMANY: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 140
TABLE 132 GERMANY: RECOMBINANT PROTEINS MARKET, BY END USER, 2020–2027 (USD MILLION) 140
9.3.2 UK 140
9.3.2.1 Government initiatives to drive market growth in UK 140
TABLE 133 UK: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 141
TABLE 134 UK: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 142
TABLE 135 UK: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 142
TABLE 136 UK: RECOMBINANT PROTEINS MARKET, BY END USER, 2020–2027 (USD MILLION) 143
9.3.3 FRANCE 143
9.3.3.1 Infrastructural development and rising life science R&D expected to support market growth 143
TABLE 137 FRANCE: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 144
TABLE 138 FRANCE: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 145
TABLE 139 FRANCE: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 145
TABLE 140 FRANCE: RECOMBINANT PROTEINS MARKET, BY END USER, 2020–2027 (USD MILLION) 146
9.3.4 ITALY 146
9.3.4.1 Life science research investments and favorable funding scenario to drive growth 146
TABLE 141 ITALY: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 147
TABLE 142 ITALY: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 147
TABLE 143 ITALY: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 148
TABLE 144 ITALY: RECOMBINANT PROTEINS MARKET, BY END USER, 2020–2027 (USD MILLION) 148
9.3.5 SPAIN 148
9.3.5.1 Favorable scenario for research initiatives to propel market growth 148
TABLE 145 SPAIN: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 149
TABLE 146 SPAIN: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 150
TABLE 147 SPAIN: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 150
TABLE 148 SPAIN: RECOMBINANT PROTEINS MARKET, BY END USER, 2020–2027 (USD MILLION) 151
9.3.6 REST OF EUROPE 151
TABLE 149 ROE: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 152
TABLE 150 ROE: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 152
TABLE 151 ROE: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 153
TABLE 152 ROE: RECOMBINANT PROTEINS MARKET, BY END USER, 2020–2027 (USD MILLION) 153
9.4 ASIA PACIFIC 154
TABLE 153 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 156
TABLE 154 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 156
TABLE 155 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 157
TABLE 156 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 157
TABLE 157 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET, BY END USER, 2020–2027 (USD MILLION) 158
9.4.1 JAPAN 158
9.4.1.1 Advanced healthcare infrastructure to support market growth 158
TABLE 158 JAPAN: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 159
TABLE 159 JAPAN: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 159
TABLE 160 JAPAN: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 160
TABLE 161 JAPAN: RECOMBINANT PROTEINS MARKET, BY END USER, 2020–2027 (USD MILLION) 160
9.4.2 CHINA 160
9.4.2.1 China to witness highest growth in Asia Pacific market 160
TABLE 162 CHINA: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 161
TABLE 163 CHINA: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 162
TABLE 164 CHINA: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 162
TABLE 165 CHINA: RECOMBINANT PROTEINS MARKET, BY END USER, 2020–2027 (USD MILLION) 163
9.4.3 INDIA 163
9.4.3.1 Strong biopharmaceutical growth and rising demand for pharmaceuticals are key market drivers 163
TABLE 166 INDIA: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 164
TABLE 167 INDIA: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 165
TABLE 168 INDIA: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 165
TABLE 169 INDIA: RECOMBINANT PROTEINS MARKET, BY END USER, 2020–2027 (USD MILLION) 166
9.4.4 REST OF ASIA PACIFIC 166
TABLE 170 ROAPAC: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 167
TABLE 171 ROAPAC: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 168
TABLE 172 ROAPAC: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 168
TABLE 173 ROAPAC: RECOMBINANT PROTEINS MARKET, BY END USER, 2020–2027 (USD MILLION) 169
9.5 LATIN AMERICA 169
9.5.1 GROWTH IN BIOPHARMACEUTICAL INDUSTRY TO DRIVE DEMAND FOR RECOMBINANT PROTEINS 169
TABLE 174 LATIN AMERICA: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 170
TABLE 175 LATIN AMERICA: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 171
TABLE 176 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 171
TABLE 177 LATIN AMERICA: RECOMBINANT PROTEINS MARKET, BY END USER, 2020–2027 (USD MILLION) 172
9.6 MIDDLE EAST & AFRICA 172
9.6.1 INCREASING GOVERNMENT INVESTMENTS IN HEALTHCARE SECTOR AND GROWING PHARMACEUTICAL INDUSTRY TO SUPPORT MARKET GROWTH 172
TABLE 178 MIDDLE EAST & AFRICA: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 173
TABLE 179 MIDDLE EAST & AFRICA: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 174
TABLE 180 MIDDLE EAST & AFRICA: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 174
TABLE 181 MIDDLE EAST & AFRICA: RECOMBINANT PROTEINS MARKET, BY END USER, 2020–2027 (USD MILLION) 175
 
10 COMPETITIVE LANDSCAPE 176
10.1 OVERVIEW 176
FIGURE 25 KEY PLAYERS ADOPTED ORGANIC AND INORGANIC GROWTH STRATEGIES BETWEEN 2019 AND 2022 176
10.2 MARKET SHARE ANALYSIS 177
FIGURE 26 RECOMBINANT PROTEINS MARKET: MARKET SHARE ANALYSIS, 2021 (TOP 4 PLAYERS) 177
TABLE 182 RECOMBINANT PROTEINS MARKET: DEGREE OF COMPETITION 178
10.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS 179
FIGURE 27 REVENUE SHARE ANALYSIS OF PLAYERS IN RECOMBINANT PROTEINS MARKET (TOP 4) 179
10.4 COMPANY EVALUATION MATRIX: KEY PLAYERS (2021) 180
10.4.1 VENDOR INCLUSION CRITERIA 180
10.4.2 STARS 180
10.4.3 EMERGING LEADERS 180
10.4.4 PERVASIVE PLAYERS 180
10.4.5 PARTICIPANTS 180
FIGURE 28 RECOMBINANT PROTEINS MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS (2021) 181
10.5 COMPANY EVALUATION MATRIX: START-UPS/SMES (2021) 182
10.5.1 PROGRESSIVE COMPANIES 182
10.5.2 STARTING BLOCKS 182
10.5.3 RESPONSIVE COMPANIES 182
10.5.4 DYNAMIC COMPANIES 182
FIGURE 29 RECOMBINANT PROTEINS MARKET: COMPANY EVALUATION MATRIX FOR START-UPS/SMES (2021) 183
10.6 COMPETITIVE BENCHMARKING OF TOP 25 COMPANIES 184
10.6.1 OVERALL FOOTPRINT OF TOP 25 COMPANIES 184
FIGURE 30 FOOTPRINT ANALYSIS OF KEY PLAYERS IN RECOMBINANT PROTEINS MARKET 184
10.7 COMPETITIVE BENCHMARKING OF KEY START-UPS/SMES 185
TABLE 183 RECOMBINANT PROTEINS MARKET: DETAILED LIST OF KEY START-UPS/SMES 185
TABLE 184 RECOMBINANT PROTEINS MARKET: COMPETITIVE BENCHMARKING OF KEY START-UPS/SMES 186
10.8 COMPETITIVE SCENARIO 186
10.8.1 PRODUCT LAUNCHES AND APPROVALS (2019–2022) 186
10.8.2 DEALS (2019–2022) 187
10.8.3 EXPANSIONS (2019–2022) 188
 
11 COMPANY PROFILES 189
11.1 KEY PLAYERS 189
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
11.1.1 BIO-TECHNE CORPORATION 189
TABLE 185 R&D SYSTEMS: BUSINESS OVERVIEW 189
FIGURE 31 BIO‑TECHNE CORPORATION: COMPANY SNAPSHOT (2021) 190
11.1.2 THERMO FISHER SCIENTIFIC, INC. 194
TABLE 186 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW 194
FIGURE 32 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2021) 195
11.1.3 MERCK KGAA 198
TABLE 187 MERCK KGAA: BUSINESS OVERVIEW 198
FIGURE 33 MERCK KGAA: COMPANY SNAPSHOT (2021) 199
11.1.4 ABCAM PLC 202
TABLE 188 ABCAM PLC: BUSINESS OVERVIEW 202
FIGURE 34 ABCAM PLC: COMPANY SNAPSHOT (2021) 202
11.1.5 ABNOVA CORPORATION 205
TABLE 189 ABNOVA CORPORATION: BUSINESS OVERVIEW 205
11.1.6 BIOLEGEND 207
TABLE 190 BIOLEGEND: BUSINESS OVERVIEW 207
11.1.7 BIO-RAD LABORATORIES, INC. 209
TABLE 191 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW 209
FIGURE 35 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2021) 210
11.1.8 BPS BIOSCIENCE, INC. 211
TABLE 192 BPS BIOSCIENCE, INC.: BUSINESS OVERVIEW 211
11.1.9 ENZO LIFE SCIENCES, INC. 213
TABLE 193 ENZO LIFE SCIENCES, INC.: BUSINESS OVERVIEW 213
FIGURE 36 ENZO BIOCHEM, INC.: COMPANY SNAPSHOT (2021) 214
11.1.10 GENSCRIPT BIOTECH CORPORATION 216
FIGURE 37 GENSCRIPT BIOTECH CORPORATION: COMPANY SNAPSHOT (2021) 217
11.1.11 MILTENYI BIOTEC 220
TABLE 195 MILTENYI BIOTECH: BUSINESS OVERVIEW 220
11.1.12 PROTEINTECH GROUP 222
TABLE 196 PROTEINTECH GROUP: BUSINESS OVERVIEW 222
11.1.13 SINO BIOLOGICAL INC. 224
TABLE 197 SINO BIOLOGICAL INC.: BUSINESS OVERVIEW 224
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
11.2 OTHER PLAYERS 227
11.2.1 ACROBIOSYSTEMS 227
11.2.2 AVIVA SYSTEMS BIOLOGY CORPORATION 228
11.2.3 CELLGENIX GMBH 228
11.2.4 ICOSAGEN AS 229
11.2.5 NEUROMICS 230
11.2.6 PROSPEC-TECHNOGENE LTD. 231
11.2.7 PROTEOGENIX 232
11.2.8 RAYBIOTECH, INC. 233
11.2.9 LAURUS BIO (RICHCORE LIFESCIENCES PVT. LTD.) 234
11.2.10 STEMCELL TECHNOLOGIES INC. 235
11.2.11 STRESSMARQ BIOSCIENCES INC. 236
11.2.12 UNITED STATES BIOLOGICAL 237
12 APPENDIX 238
12.1 DISCUSSION GUIDE 238
12.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 242
12.3 CUSTOMIZATION OPTIONS 244
12.4 RELATED REPORTS 244
12.5 AUTHOR DETAILS 245

　

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（バイオ薬物）の最新刊レポート

MarketsandMarkets 社の最新刊レポート

本レポートと同じKEY WORD（application drug）の最新刊レポート


よくあるご質問


MarketsandMarkets社はどのような調査会社ですか?


マーケッツアンドマーケッツ（MarketsandMarkets）は通信、半導体、医療機器、エネルギーなど、幅広い市場に関する調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行って... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

お問合せはこちらから

03-3582-2531

電話お問合せもお気軽に

 

2024/07/04　10:27

162.47 円

175.74 円

209.86 円

ページTOPに戻る

株式会社 データリソース　Data Resources, Inc.
東京都港区赤坂1-14-5　アークヒルズエグゼクティブタワー N313

電話：03-3582-2531
FAX：03-3582-2861
Eメール：office@dri.co.jp

FAQ サイトマップ プライバシーポリシー お問合せ

関連会社:
株式会社ユーディーアール

COPYRIGHT(C) 2011-2023　DATA RESOURCES, Inc. ALL RIGHTS RESERVED.